



1624
CW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 24th of June 2005.

By

(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Laura C. Blumberg, et al.

Serial No.: 09/972,177

Filed: October 5, 2001

Title: BRIDGED PIPERAZINE
DERIVATIVES

)
)
)
)
)
)
)
)
)
)

Group Art Unit: 1624

Examiner: Brenda Libby Coleman

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Sir:

Applicants hereby submit to the U.S. Patent and Trademark Office form PTO-FB-A820 and a copy of the documents cited therein to ensure compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. This submission is intended to augment, and not replace, the Information Disclosure Statement filed previously on August 26, 2002.

In the judgment of the undersigned, portions of the documents cited in form PTO-FB-A820 may be material to the present application, however, the filing of this Information Disclosure Statement shall not be construed to be an admission that the documents cited are, or are considered to be, material with regard to patentability as defined in 37 C.F.R. § 1.56(b). The documents have not been reviewed in sufficient detail to make any other


representation and, in particular, no representation is intended as to the relative importance of any portion of the documents. This statement is not a representation that the listed documents have an effective date early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

As this Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination, Applicants believe that no fee is due pursuant to 37 C.F.R. § 1.97(b)(4). However, to the extent a fee is necessary, please apply any charges or credits to Deposit Account No. 16-1445.

Respectfully submitted,

Date:

June 24, 2005



Christopher J. Verni
Attorney for Applicants
Reg. No. 48,322

Customer No. 28523

Pfizer Inc.


Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 686-2032

Doc. #: 83165v1



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC11076A		SERIAL NO. 09/972,177		
										APPLICANT Laura C. Blumberg, et al.				
										FILING DATE October 5, 2001		GROUP 1624		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	3	1	1	9	7	4	2	1/28/94	Heimlich, et al.	167	82		
	US	9	4	9	2	3	9	7	1/27/70	Peters, et al.	424	20		
	US	9	5	9	8	2	1	4	11/3/70	Polli, et al.	424	19		
	US	4	6	6	3	6	9	8	11/29/77	Groppenbacher	424	33		
	US	4	1	7	3	6	2	6	11/6/79	Dempski, et al.	424	19		
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	1	7	2	7	2	8	3/14/01	International	C07D	295/185		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Combadiere, C., et al., <u>J. Biol. Chem.</u> , "Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC Chemokine Receptors 1 and 2B", Vol. 270, No. 50, pages 29671-29675 (1995)												
		Cook, et al., <u>Science</u> , "Requirement of MIP-1-alpha for an Inflammatory Response to Viral Infection", Vol. 269, page 1583 (1995)												
		Kuna, et al., <u>J. Allergy Clin. Immunol.</u> , "Allergens, IgE, Mediators, Inflammatory Mechanisms", Vol. 97, No. 1 page. 321 (1996)												
		Smith, et al., <u>J. Immunol.</u> , "Production and Function of Murine Macrophage Inflammatory Protein-1 x in Bleomycin-Induced Lung Injury", Vol. 153, page 4704 (1994)												
		Teran, L., et al., <u>J. Immunol.</u> , "Eosinophil Recruitment Following Allergen Challenge is Associated with the Release of the Chemokine RANTES into Asthmatic Airways", Vol. 157, pages 1806-1812 (1996)												
		Current Protocols in Immunology, Chapter 6. Cytokines and Their Cellular Receptors: Unit 6.12-Biological Responses to Chemokine Superfamily Members: "Basic Protocol 1: Measurement of Granulocyte Chemotaxis by Chemokines Using Microche" (John Wiley and Sons, NY) 1991												
		Current Protocols in Immunology, Chapter 6: Cytokines and Their Cellular Receptors: Unit 6.12-Biological Responses to Chemokine Superfamily Members: "Basic Protocol 2: Measurement of Monocyte Chemotaxis by Chemokines Using Microchemotaxis Assays", (John Wiley and Sons, NY) 1991												
		Current Protocols in Immunology, Chapter 6. Cytokines and Their Cellular Receptors: Unit 6.12-Biological Responses to Chemokine Superfamily Members: "Basic Protocol 3: Measurement of Lymphocyte Chemotaxis By Chemokines Using Microchemotaxis Assays" (John Wiley and Sons, NY) 1991												
		U.S. Provisional No. 60/193,789 filed March 31, 2000 as PC10770												
EXAMINER														
DATE CONSIDERED														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE